<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02430805</url>
  </required_header>
  <id_info>
    <org_study_id>HYPERCARE(english v. 1.0)JRPB3</org_study_id>
    <secondary_id>Cpp : 07.11.11</secondary_id>
    <secondary_id>Dgs: 2007-0537</secondary_id>
    <nct_id>NCT02430805</nct_id>
  </id_info>
  <brief_title>Predisposition and Transition Mechanisms From Arterial Hypertension to Heart Failure</brief_title>
  <acronym>Hypercare</acronym>
  <official_title>Genetics and Genomics of Hypertension Associated With Microinflammation, Oxydative Stress, Chronic Renal Disease and Heart Failure (A2-B2-B3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Network of Excellence 6 PCRD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims at investigating the genetic, genomic and proteomic basis of hypertension&#xD;
      and susceptibility to hypertension-related end organ damage (renal damage and heart failure).&#xD;
      It will include cross sectional as well as follow-up studies with a large number of subjects&#xD;
      and variety of phenotypes, to explore the pathophysiology of hypertension and&#xD;
      hypertension-related disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In all index patients and recruited family members, recorded data will include the following&#xD;
      :&#xD;
&#xD;
        -  Past medical history, drug history and family history&#xD;
&#xD;
        -  Physical examination&#xD;
&#xD;
        -  Height, weight, waist and hip circumference&#xD;
&#xD;
        -  Cardiac examination&#xD;
&#xD;
        -  Vascular examination&#xD;
&#xD;
        -  Blood pressure&#xD;
&#xD;
        -  Plasma and urine samples&#xD;
&#xD;
        -  Body composition (DEXA)&#xD;
&#xD;
        -  Tissue Doppler imaging&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>genetic biomarkers</measure>
    <time_frame>time point 1 : first day ; Time point</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>oxidative stress markers</measure>
    <time_frame>time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microinflammation markers</measure>
    <time_frame>time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function and damage markers</measure>
    <time_frame>time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac and large artery growth, remodelling dysfunction and failure markers</measure>
    <time_frame>time point 1 : first day ; Time point 2 : 2 years ; Time point 3 : 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>NOE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>multicentric family-based cohort. prospective and transversal study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dna extraction and genotyping</intervention_name>
    <description>blood and urine sample</description>
    <arm_group_label>NOE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  index patient :&#xD;
&#xD;
               -  Caucasian patients of either sex who were diagnosed to have essential&#xD;
                  hypertension (as defined below) before the age of 50 y.&#xD;
&#xD;
               -  The index patient should not be older than 60 years at the time of enrolment.&#xD;
&#xD;
               -  Definition of hypertension for the index patient:&#xD;
&#xD;
                    -  If untreated: Systolic blood pressure &gt; 160 mmHg and/or diastolic blood&#xD;
                       pressure &gt; 95 mmHg.&#xD;
&#xD;
                    -  If already on treatment: Treatment with more of 2 different antihypertensive&#xD;
                       drugs at the time of enrolment.&#xD;
&#xD;
               -  At least three first degree relatives of whom at least one should be affected and&#xD;
                  at least one be from a different generation (parents or offspring aged 18 years&#xD;
                  or above) must be willing to participate in the family study. For definition of&#xD;
                  hypertension in relatives of the index patient see below.&#xD;
&#xD;
               -  Written informed consent&#xD;
&#xD;
          -  family&#xD;
&#xD;
               -  at least three other first degree relatives must be willing to participate in the&#xD;
                  family study:&#xD;
&#xD;
               -  at least one first-degree relative must be affected with diagnosis of&#xD;
                  hypertension made before age of 50 years AND&#xD;
&#xD;
               -  at least one first degree relative must be from a different generation (offspring&#xD;
                  or parents).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  index patient :&#xD;
&#xD;
               -  Any known form of secondary hypertension, including sleep apnoea syndrome&#xD;
&#xD;
               -  Any known previous clinical complications of hypertension (angina, MI, stroke,&#xD;
                  TIA, peripheral artery disease) at any time&#xD;
&#xD;
               -  Any known renal disease, including GFR &lt; 60 mL/min as estimated by the&#xD;
                  abbreviated MDRD formula, or kidney stones&#xD;
&#xD;
               -  Kidney or other organ transplantation&#xD;
&#xD;
               -  Type 1 diabetes mellitus&#xD;
&#xD;
               -  Heart failure stage D (AHA/ACC criteria)&#xD;
&#xD;
               -  Any malignant concomitant diseases or history of malignant diseases within the&#xD;
                  last five years, with exception of treated squamous skin cancer or basalioma&#xD;
&#xD;
               -  Clinical or laboratory signs of acute infection, especially urinary tract&#xD;
                  infection&#xD;
&#xD;
               -  Systemic inflammatory diseases, such as autoimmune diseases, connective tissue&#xD;
                  diseases or collagenoses.&#xD;
&#xD;
               -  Steroids or any other immunosuppressive drug&#xD;
&#xD;
               -  Severe known liver disease (ALT or gamma-GT above three-fold of upper normal&#xD;
                  limit)&#xD;
&#xD;
               -  Current alcohol consume of more than 21 drinks/week (1 drink = a bottle (0,33 l)&#xD;
                  beer, a glass (0,2 l) of wine, or 4 cl = 40 ml of spirit (40%)) or drug abuse&#xD;
                  such as cocaine&#xD;
&#xD;
          -  family&#xD;
&#xD;
               -  any organ transplantation&#xD;
&#xD;
               -  any malignant concomitant disease&#xD;
&#xD;
               -  acute infection&#xD;
&#xD;
               -  systemic inflammatory disease&#xD;
&#xD;
               -  severe liver disease&#xD;
&#xD;
               -  current alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>faiez ZANNAD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Hospital, Nancy, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre D'Investigation Clinique de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Brabois adulte</name>
      <address>
        <city>Nancy</city>
        <state>Lorraine</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>February 5, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>microinflammation and oxidative stress</keyword>
  <keyword>renal disease</keyword>
  <keyword>heart failure</keyword>
  <keyword>genetics markers</keyword>
  <keyword>genomics markers</keyword>
  <keyword>proteomics markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

